Century Therapeutics, Inc.
NASDAQ:IPSCBiotechnology
Healthcare
$1.32 +0.48%
+$0.01 today
- Market cap
- $239.71M
- Beta
- 1.57
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.25
52W Low $0.44High $3.04
Volume 0.82M
Average 1.12M
Income Statement
Follow revenue through to earnings.
Revenue
$109.16M
FY 2025 · Annual
+1556.8% YoYOperating Income
-$15.04M
FY 2025 · Annual
Net Income
-$9.58M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 5.2M | 2.24M | 6.59M | 109.16M |
| Cost of Revenue | 4.58M | 0 | 0 | 0 | 13.1M |
| Gross Profit | (4.58M) | 5.2M | 2.24M | 6.59M | 96.06M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 88.0% |
| Research & Development | 75.65M | 97.17M | 92.71M | 107.24M | 95.67M |
| Selling, General & Admin | 14.65M | 31.86M | 34.71M | 33.16M | 24M |
| Operating Expenses | 90.3M | 139.03M | 148.78M | 144.73M | 111.1M |
| Depreciation & Amortization | 4.58M | 8.44M | 13.04M | 13.3M | 13.1M |
| EBITDA | (89.92M) | (121.2M) | (121.21M) | (111.47M) | 3.45M |
| EBITDA Margin | — | -2331.2% | -5423.2% | -1691.8% | 3.2% |
| Operating Income | (94.88M) | (133.83M) | (146.55M) | (138.14M) | (15.04M) |
| Operating Margin | — | -2574.2% | -6556.9% | -2096.5% | -13.8% |
| Interest Income | 898K | 2.99M | 12.68M | 13.01M | 7.35M |
| Interest Expense | 1.28M | 0 | 540K | 0 | 0 |
| Other Income / Expenses | (898K) | 2.99M | 11.75M | 13.36M | 5.39M |
| Income Before Tax | (95.78M) | (130.84M) | (134.79M) | (124.78M) | (9.65M) |
| Pre-Tax Margin | — | -2516.7% | -6031.0% | -1893.7% | -8.8% |
| Income Tax Expense | 43K | 91K | 1.88M | 1.79M | (68K) |
| Net Income | (95.82M) | (130.93M) | (136.67M) | (126.57M) | (9.58M) |
| Net Margin | — | -2518.4% | -6115.1% | -1920.9% | -8.8% |
| EPS (Basic) | (1.74) | (2.27) | (2.30) | (1.61) | (0.11) |
| EPS (Diluted) | (1.74) | (2.27) | (2.30) | (1.61) | (0.11) |
| 55.01M | 57.76M | 59.31M | 78.65M | 86.56M | |
| 55.01M | 57.76M | 59.31M | 78.65M | 86.56M |
IPSC Earnings Waterfall · TTM
NASDAQ:IPSC · Revenue to Net Income
Key Ratios
EPS$-1.25
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.0
P/S Ratio0.0
Analysis
$0 of revenue converted into -$107.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.25, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 | |
| 8-K | Current report | Oct 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 15, 2026 |
How much revenue does IPSC generate?
Century Therapeutics, Inc. (IPSC) reported $109.16M of revenue in fiscal 2025.
Is IPSC profitable?
Century Therapeutics, Inc. (IPSC) reported -$9.58M of net income, with a net margin of -8.8%.
Continue the stock analysis
Jump to another research area for this company.